Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411568 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPK1LMNATDP1ATM | |
| SCHEMBL21100607 | 0.86 | L3MBTL1 (0.43) | L3MBTL1MAPK1LMNATDP1ATM | |
| SCHEMBL21045171 | 0.82 | NPC1 (0.57) | L3MBTL1MAPK1LMNATDP1ATM | |
| SCHEMBL29411389 | 0.82 | NPC1 (0.57) | L3MBTL1MAPK1LMNATDP1ATM | |
| SCHEMBL21045514 | 0.79 | NPC1 (0.70) | L3MBTL1MAPK1LMNATDP1ATM | |
| SCHEMBL29411507 | 0.79 | NPC1 (0.70) | L3MBTL1MAPK1LMNATDP1ATM | |
| SCHEMBL29411556 | 0.78 | NPC1 (0.62) | L3MBTL1MAPK1LMNATDP1ATM | |
| SCHEMBL21045259 | 0.78 | NPC1 (0.62) | L3MBTL1MAPK1LMNATDP1ATM | |
| SCHEMBL21045507 | 0.77 | L3MBTL1 (0.47) | L3MBTL1MAPK1LMNATDP1ATM | |
| SCHEMBL29411661 | 0.77 | L3MBTL1 (0.47) | L3MBTL1MAPK1LMNATDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| WO-2019113242-A1 | TUBULIN INHIBITORS | Lin BioScience, LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | L3MBTL1 2058/4885MAPK1 2169/4885LMNA 2547/4885 |
| US-11040945-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | L3MBTL1 2058/4885MAPK1 2169/4885LMNA 2547/4885 |
| US-20190169127-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | L3MBTL1 2058/4885MAPK1 2169/4885LMNA 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.